Publication
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
Veena Hoffman, Jesper Hallas, Marie Linder, Andrea V. Margulis, Brandon T. Suehs, Alejandro Arana, Kelesitse Phiri, Cheryl Enger, Libby Horter, Ingvild Odsbu, Morten Olesen, Susana Perez-Gutthann, Yihua Xu, Nina Sahlertz Kristiansen, Kwame Appenteng, Stefan de Vogel, John D. Seeger, Cheryl Enger, John Seeger, Veena Hoffman, Kelesitse Phiri, Jesper Hallas, Morten Olesen, Nina Sahlertz Kristiansen, Shahram Bahmanyar, Marie Linder, Helle Kieler, Ingvild Odsbu, Alejandro Arana, Lisa McQuay, Andrea Margulis, Susana Perez-Gutthann, Ryan Ziemiecki, Su Bunniran, Brandon Suehs, Claudia Uribe, Yihua Xu, Libby Horter, Kwame Appenteng, Stefan de Vogel, Noah Jamie Robinson, Songlin Xue, Josie Wolfram, Achim Steup, Jena Giese-Pagac, Raymond van Aarle, Neha Sheth, David Burns, Natalie Boone, Mary Beth Blauwet, Milbhor D’Silva, Billy Franks, Willem Jan Atsma, Tim Auton, Edeltraut Garbe, Anders Ekbom, Todd Lee, Noel Weiss, John Rumsfeld, Sara Yuewen Gao, Laura Karslake, Nan Liu, Katherine Reed, Bruce Turnbull, Jing Yang, Nicole Brooks, Kathleen Mortimer
Drug Safety, July 2021, Springer Science + Business Media
DOI: 10.1007/s40264-021-01095-7